Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,055 recalls · Class II, newest first

Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1403-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1402-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1401-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1400-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1399-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1397-2014
Class II · Moderate risk

Mic Plus B12

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1393-2014
Class II · Moderate risk

Bystolic (nebivolol)

Failed Dissolution Specifications: One lot of product is being voluntarily recalled because dissolution test results failed to meet specification throughout the product's shelf life.

Terminated Dissolution failure Forest Pharmaceuticals Inc NDC 0456-1420-30 D-1348-2014
Class II · Moderate risk

Hemo-Stat Solution

Marketed without an Approved NDA/ANDA; product is being manufactured and distributed without a NDC number

Terminated Unapproved drug Axcentria Pharmaceuticals, LLC D-1434-2014
Class II · Moderate risk

Fosphenytoin Sodium Injection

Presence of Particular Matter: Potential glass delamination and consistent with glass particulates observed in sample vials.

Terminated Particulate / foreign matter Fresenius Kabi USA, LLC NDC 63323-403-10 D-1429-2014
Class II · Moderate risk

Fosphenytoin Sodium Injection

Presence of Particular Matter: Potential glass delamination and consistent with glass particulates observed in sample vials.

Terminated Particulate / foreign matter Fresenius Kabi USA, LLC NDC 63323-403-02 D-1428-2014
Class II · Moderate risk

Calcitriol Oral Solution 1 mcg/mL

Failed Impurity/Degradation Specification; out of specification for trans-calcitriol degradant at the 9 month stability time point

Terminated Impurity / degradation Boehringer Ingelheim Roxane Inc NDC 0054-3120-41 D-1427-2014
Class II · Moderate risk

Dextroamphetamine Sulfate Tablets

Failed Impurities/Degradation Specifications: this product is being recalled due to an out of specification test result for impurities during stability testing.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0555-0953-02 D-1408-2014
Class II · Moderate risk

Red Yeast Rice High Potency Dietary Supplement

Marketed Without An Approved NDA/ANDA: Product is being recalled due to excessive levels of lovastatin. Lovastatin is an FDA approved drug making this dietary supplement an unapproved new drug.

Terminated Unapproved drug Independent Nutrition Center, Inc. D-1349-2014
Class II · Moderate risk

Sterile Water for Injection

Marketed Without An Approved NDA/ANDA: Product is sold over the counter whose labeling indicates it is to be used for parenteral injection.

Completed Unapproved drug Flawless Beauty LLC D-1321-2014

Recalls by year